S0338, Imatinib Mesylate and Capecitabine in Treating Women With Progressive Stage IV Breast Cancer

NCT00087152 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

27

Enrollment

NIH

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Capecitabine
DRUG: Imatinib mesylate

Sponsor

National Cancer Institute (NCI)